11.83

1.83% -0.22

Pre-market: 11.99 0.16 +1.35%

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $11.83, with a volume of 45,578. It is down -1.83% in the last 24 hours and down -25.69% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Previous Close:

$12.05

Open:

$11.87

24h Volume:

45,578

Relative Volume:

0.49

Market Cap:

$267.88M

Revenue:

$26.00M

Net Income/Loss:

$-219.71M

P/E Ratio:

-0.2376

EPS:

-49.8

Net Cash Flow:

$-51.37M

1W Performance:

+12.67%

1M Performance:

-25.69%

6M Performance:

-42.52%

1Y Performance:

-43.40%

1-Day Range:

$11.51

$12.05

1-Week Range:

$9.545

$12.18

52-Week Range:

$8.85

$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	11.83	267.88M	26.00M	-219.71M	-51.37M	-49.80
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

04:07 AM

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLC - Defense World

04:07 AM

01:36 AM

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.67 Consensus Target Price from Brokerages - Defense World

01:36 AM

Apr 25, 2025

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - ADVFN

Apr 25, 2025

Apr 24, 2025

Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Shows Efficacy and Safety in Myasthenia Gravis in Phase 2 Study - CGTLive®

Apr 24, 2025

Apr 19, 2025

JPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Apr 19, 2025

Apr 18, 2025

After-Market Momentum Builds For ASP Isotopes (ASPI) Amid Secondary Listing News - Stocks Telegraph

Apr 18, 2025

Apr 16, 2025

Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Apr 16, 2025

Apr 12, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World

Apr 12, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 12, 2025

Apr 11, 2025

Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock - Investing.com Australia

Apr 11, 2025

Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock By Investing.com - Investing.com South Africa

Apr 11, 2025

Apr 09, 2025

Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter

Apr 09, 2025

US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Benzinga

Apr 09, 2025

Apr 08, 2025

Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech

Apr 08, 2025

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com

Apr 08, 2025

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga

Apr 08, 2025

Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks

Apr 08, 2025

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire

Apr 08, 2025

Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan

Apr 08, 2025

Apr 03, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World

Apr 03, 2025

Apr 02, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Apr 02, 2025

Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan

Apr 02, 2025

Apr 01, 2025

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025

Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan

Apr 01, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Apr 01, 2025

Mar 29, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World

Mar 29, 2025

Mar 23, 2025

Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo

Mar 23, 2025

Mar 21, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India

Mar 21, 2025

Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa

Mar 20, 2025

Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World

Mar 20, 2025

Mar 18, 2025

Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st

Mar 18, 2025

Mar 17, 2025

Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada

Mar 17, 2025

Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada

Mar 17, 2025

Mar 16, 2025

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st

Mar 15, 2025

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Mar 15, 2025

Mar 14, 2025

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance

Mar 14, 2025

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 14, 2025

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks

Mar 14, 2025

Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks

Mar 14, 2025

Mar 13, 2025